Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation

Amanda Soler, Ian Hunter, Gregory Joseph, Rebecca Hutcheson, Brenda Hutcheson, Jenny Yang, Frank Fan Zhang, Sachindra Raj Joshi, Chastity Bradford, Katherine H. Gotlinger, Rachana Maniyar, John R. Falck, Spencer Proctor, Michal Laniado Schwartzman, Sachin A. Gupte, Petra Rocic

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Arterial stiffness plays a causal role in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome P450 (CYP450)-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive animal models and loosely associated with obesity in humans. However, the role of 20-HETE in the regulation of large artery remodeling in metabolic syndrome has not been investigated. We hypothesized that elevated 20-HETE in metabolic syndrome increases matrix metalloproteinase 12 (MMP12) activation leading to increased degradation of elastin, increased large artery stiffness and increased systolic blood pressure. 20-HETE production was increased ∼7 fold in large, conduit arteries of metabolic syndrome (JCR:LA-cp, JCR) vs. normal Sprague-Dawley (SD) rats. This correlated with increased elastin degradation (∼7 fold) and decreased arterial compliance (∼75% JCR vs. SD). 20-HETE antagonists blocked elastin degradation in JCR rats concomitant with blocking MMP12 activation. 20-HETE antagonists normalized, and MMP12 inhibition (pharmacological and MMP12-shRNA-Lnv) significantly improved (∼50% vs. untreated JCR) large artery compliance in JCR rats. 20-HETE antagonists also decreased systolic (182 ± 3 mmHg JCR, 145 ± 3 mmHg JCR + 20-HETE antagonists) but not diastolic blood pressure in JCR rats. Whereas diastolic pressure was fully angiotensin II (Ang II)-dependent, systolic pressure was only partially Ang II-dependent, and large artery stiffness was Ang II-independent. Thus, 20-HETE-dependent regulation of systolic blood pressure may be a unique feature of metabolic syndrome related to high 20-HETE production in large, conduit arteries, which results in increased large artery stiffness and systolic blood pressure. These findings may have implications for management of systolic hypertension in patients with metabolic syndrome.

Original languageEnglish (US)
JournalJournal of Molecular and Cellular Cardiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Matrix Metalloproteinase 12
Vascular Stiffness
Blood Pressure
Hypertension
Arteries
Acids
Elastin
Angiotensin II
Compliance
Arachidonic Acid
Cytochrome P-450 Enzyme System
Small Interfering RNA
Sprague Dawley Rats
Animal Models
Obesity

Keywords

  • 20-HETE
  • Arterial compliance
  • Elastin
  • Macrocirculation
  • MMP12
  • Systolic hypertension

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation. / Soler, Amanda; Hunter, Ian; Joseph, Gregory; Hutcheson, Rebecca; Hutcheson, Brenda; Yang, Jenny; Zhang, Frank Fan; Joshi, Sachindra Raj; Bradford, Chastity; Gotlinger, Katherine H.; Maniyar, Rachana; Falck, John R.; Proctor, Spencer; Schwartzman, Michal Laniado; Gupte, Sachin A.; Rocic, Petra.

In: Journal of Molecular and Cellular Cardiology, 01.01.2018.

Research output: Contribution to journalArticle

Soler, A, Hunter, I, Joseph, G, Hutcheson, R, Hutcheson, B, Yang, J, Zhang, FF, Joshi, SR, Bradford, C, Gotlinger, KH, Maniyar, R, Falck, JR, Proctor, S, Schwartzman, ML, Gupte, SA & Rocic, P 2018, 'Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation', Journal of Molecular and Cellular Cardiology. https://doi.org/10.1016/j.yjmcc.2018.02.005
Soler, Amanda ; Hunter, Ian ; Joseph, Gregory ; Hutcheson, Rebecca ; Hutcheson, Brenda ; Yang, Jenny ; Zhang, Frank Fan ; Joshi, Sachindra Raj ; Bradford, Chastity ; Gotlinger, Katherine H. ; Maniyar, Rachana ; Falck, John R. ; Proctor, Spencer ; Schwartzman, Michal Laniado ; Gupte, Sachin A. ; Rocic, Petra. / Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation. In: Journal of Molecular and Cellular Cardiology. 2018.
@article{b6db5ee676744875959f5fbf4ba980f3,
title = "Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation",
abstract = "Arterial stiffness plays a causal role in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome P450 (CYP450)-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive animal models and loosely associated with obesity in humans. However, the role of 20-HETE in the regulation of large artery remodeling in metabolic syndrome has not been investigated. We hypothesized that elevated 20-HETE in metabolic syndrome increases matrix metalloproteinase 12 (MMP12) activation leading to increased degradation of elastin, increased large artery stiffness and increased systolic blood pressure. 20-HETE production was increased ∼7 fold in large, conduit arteries of metabolic syndrome (JCR:LA-cp, JCR) vs. normal Sprague-Dawley (SD) rats. This correlated with increased elastin degradation (∼7 fold) and decreased arterial compliance (∼75{\%} JCR vs. SD). 20-HETE antagonists blocked elastin degradation in JCR rats concomitant with blocking MMP12 activation. 20-HETE antagonists normalized, and MMP12 inhibition (pharmacological and MMP12-shRNA-Lnv) significantly improved (∼50{\%} vs. untreated JCR) large artery compliance in JCR rats. 20-HETE antagonists also decreased systolic (182 ± 3 mmHg JCR, 145 ± 3 mmHg JCR + 20-HETE antagonists) but not diastolic blood pressure in JCR rats. Whereas diastolic pressure was fully angiotensin II (Ang II)-dependent, systolic pressure was only partially Ang II-dependent, and large artery stiffness was Ang II-independent. Thus, 20-HETE-dependent regulation of systolic blood pressure may be a unique feature of metabolic syndrome related to high 20-HETE production in large, conduit arteries, which results in increased large artery stiffness and systolic blood pressure. These findings may have implications for management of systolic hypertension in patients with metabolic syndrome.",
keywords = "20-HETE, Arterial compliance, Elastin, Macrocirculation, MMP12, Systolic hypertension",
author = "Amanda Soler and Ian Hunter and Gregory Joseph and Rebecca Hutcheson and Brenda Hutcheson and Jenny Yang and Zhang, {Frank Fan} and Joshi, {Sachindra Raj} and Chastity Bradford and Gotlinger, {Katherine H.} and Rachana Maniyar and Falck, {John R.} and Spencer Proctor and Schwartzman, {Michal Laniado} and Gupte, {Sachin A.} and Petra Rocic",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.yjmcc.2018.02.005",
language = "English (US)",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation

AU - Soler, Amanda

AU - Hunter, Ian

AU - Joseph, Gregory

AU - Hutcheson, Rebecca

AU - Hutcheson, Brenda

AU - Yang, Jenny

AU - Zhang, Frank Fan

AU - Joshi, Sachindra Raj

AU - Bradford, Chastity

AU - Gotlinger, Katherine H.

AU - Maniyar, Rachana

AU - Falck, John R.

AU - Proctor, Spencer

AU - Schwartzman, Michal Laniado

AU - Gupte, Sachin A.

AU - Rocic, Petra

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Arterial stiffness plays a causal role in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome P450 (CYP450)-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive animal models and loosely associated with obesity in humans. However, the role of 20-HETE in the regulation of large artery remodeling in metabolic syndrome has not been investigated. We hypothesized that elevated 20-HETE in metabolic syndrome increases matrix metalloproteinase 12 (MMP12) activation leading to increased degradation of elastin, increased large artery stiffness and increased systolic blood pressure. 20-HETE production was increased ∼7 fold in large, conduit arteries of metabolic syndrome (JCR:LA-cp, JCR) vs. normal Sprague-Dawley (SD) rats. This correlated with increased elastin degradation (∼7 fold) and decreased arterial compliance (∼75% JCR vs. SD). 20-HETE antagonists blocked elastin degradation in JCR rats concomitant with blocking MMP12 activation. 20-HETE antagonists normalized, and MMP12 inhibition (pharmacological and MMP12-shRNA-Lnv) significantly improved (∼50% vs. untreated JCR) large artery compliance in JCR rats. 20-HETE antagonists also decreased systolic (182 ± 3 mmHg JCR, 145 ± 3 mmHg JCR + 20-HETE antagonists) but not diastolic blood pressure in JCR rats. Whereas diastolic pressure was fully angiotensin II (Ang II)-dependent, systolic pressure was only partially Ang II-dependent, and large artery stiffness was Ang II-independent. Thus, 20-HETE-dependent regulation of systolic blood pressure may be a unique feature of metabolic syndrome related to high 20-HETE production in large, conduit arteries, which results in increased large artery stiffness and systolic blood pressure. These findings may have implications for management of systolic hypertension in patients with metabolic syndrome.

AB - Arterial stiffness plays a causal role in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome P450 (CYP450)-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive animal models and loosely associated with obesity in humans. However, the role of 20-HETE in the regulation of large artery remodeling in metabolic syndrome has not been investigated. We hypothesized that elevated 20-HETE in metabolic syndrome increases matrix metalloproteinase 12 (MMP12) activation leading to increased degradation of elastin, increased large artery stiffness and increased systolic blood pressure. 20-HETE production was increased ∼7 fold in large, conduit arteries of metabolic syndrome (JCR:LA-cp, JCR) vs. normal Sprague-Dawley (SD) rats. This correlated with increased elastin degradation (∼7 fold) and decreased arterial compliance (∼75% JCR vs. SD). 20-HETE antagonists blocked elastin degradation in JCR rats concomitant with blocking MMP12 activation. 20-HETE antagonists normalized, and MMP12 inhibition (pharmacological and MMP12-shRNA-Lnv) significantly improved (∼50% vs. untreated JCR) large artery compliance in JCR rats. 20-HETE antagonists also decreased systolic (182 ± 3 mmHg JCR, 145 ± 3 mmHg JCR + 20-HETE antagonists) but not diastolic blood pressure in JCR rats. Whereas diastolic pressure was fully angiotensin II (Ang II)-dependent, systolic pressure was only partially Ang II-dependent, and large artery stiffness was Ang II-independent. Thus, 20-HETE-dependent regulation of systolic blood pressure may be a unique feature of metabolic syndrome related to high 20-HETE production in large, conduit arteries, which results in increased large artery stiffness and systolic blood pressure. These findings may have implications for management of systolic hypertension in patients with metabolic syndrome.

KW - 20-HETE

KW - Arterial compliance

KW - Elastin

KW - Macrocirculation

KW - MMP12

KW - Systolic hypertension

UR - http://www.scopus.com/inward/record.url?scp=85042626632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042626632&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2018.02.005

DO - 10.1016/j.yjmcc.2018.02.005

M3 - Article

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -